Identification of Diagnostic Biomarkers in Prostate Cancer-related Fatigue by Construction of Predictive Models and Experimental Validation

Overview

Journal Br J Cancer

Specialty Oncology

Date 2024 Dec 15

PMID 39676131

Authors

Ming Chen

Siqi Zhou

Xiongwei He

Haiyan Wen

Affiliations

Soon will be listed here.

Abstract

Background: Cancer-related fatigue (CRF) is a prominent cancer-related complication occurring in Prostate cancer (PCa) patients, profoundly affecting prognosis. The lack of diagnostic criteria and biomarkers hampers the management of CRF.

Methods: The CRF-related data and PCa single-cell data were retrieved from the GEO database and clinical data was downloaded from the TCGA database. The univariate logistic/Cox regression analysis were used to construct the prediction models. The predictive value of models was analyzed using the ROC curve and Kaplan-Meier survival. The hub genes were screened by an intersection analysis of DEGs. The mice model of PCa and PCa-related fatigue were established, and fatigue-like behaviors of mice were detected. The expression of selected hub genes was validated by RT-PCR and IHC analysis.

Results: The diagnosis and risk models showed great predictive value both in the training and validation dataset. Five genes (Baiap2l2, Cacng4, Sytl2, Sec31b and Ms4a1) that enriched the CXCL signaling were identified as hub genes. Among all hub genes, the MS4A1 expression is the most significant in PCa-related fatigue mice.

Conclusions: We identified MS4A1 as a promising biomarker for the diagnosis of PCa-related fatigue. Our findings would lay a foundation for revealing the pathogenesis and developing therapies for PCa-related fatigue.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Kanwar N, Carmine-Simmen K, Nair R, Wang C, Moghadas-Jafari S, Blaser H . Amplification of a calcium channel subunit CACNG4 increases breast cancer metastasis. EBioMedicine. 2020; 52:102646. PMC: 7016384. DOI: 10.1016/j.ebiom.2020.102646. View

Grossberg A, Vichaya E, Christian D, Molkentine J, Vermeer D, Gross P . Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling. Cancer Res. 2017; 78(3):695-705. PMC: 5811314. DOI: 10.1158/0008-5472.CAN-17-2168. View

Landmark-Hoyvik H, Reinertsen K, Loge J, Fossa S, Borresen-Dale A, Dumeaux V . Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenomics J. 2009; 9(5):333-40. DOI: 10.1038/tpj.2009.27. View

Yang S, Chu S, Gao Y, Ai Q, Liu Y, Li X . A Narrative Review of Cancer-Related Fatigue (CRF) and Its Possible Pathogenesis. Cells. 2019; 8(7). PMC: 6679212. DOI: 10.3390/cells8070738. View

Cheng J, Yang L, Kumar V, Agarwal P . Systematic evaluation of connectivity map for disease indications. Genome Med. 2015; 6(12):540. PMC: 4278345. DOI: 10.1186/s13073-014-0095-1. View

Guo H, Peng J, Hu J, Chang S, Liu H, Luo H . BAIAP2L2 promotes the proliferation, migration and invasion of osteosarcoma associated with the Wnt/β-catenin pathway. J Bone Oncol. 2021; 31:100393. PMC: 8577457. DOI: 10.1016/j.jbo.2021.100393. View

Mattiola I, Mantovani A, Locati M . The tetraspan MS4A family in homeostasis, immunity, and disease. Trends Immunol. 2021; 42(9):764-781. DOI: 10.1016/j.it.2021.07.002. View

Chelette B, Chidomere C, Dantzer R . The GDF15-GFRAL axis mediates chemotherapy-induced fatigue in mice. Brain Behav Immun. 2022; 108:45-54. PMC: 9868083. DOI: 10.1016/j.bbi.2022.11.008. View

10.

Nazha B, Bilen M . Circulating interleukin 6, androgen deprivation therapy, and fatigue in prostate cancer: Is inflammation the link?. Cancer. 2020; 127(9):1371-1373. DOI: 10.1002/cncr.33398. View

11.

Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J . TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2022; 51(D1):D1425-D1431. PMC: 9825603. DOI: 10.1093/nar/gkac959. View

12.

Pavlasova G, Borsky M, Svobodova V, Oppelt J, cerna K, Novotna J . Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018; 32(9):2028-2031. DOI: 10.1038/s41375-018-0211-0. View

13.

Gavin A, Drummond F, Donnelly C, OLeary E, Sharp L, Kinnear H . Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments. BJU Int. 2015; 116(3):397-406. PMC: 5008189. DOI: 10.1111/bju.13036. View

14.

Pavlasova G, Mraz M . The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. PMC: 7271567. DOI: 10.3324/haematol.2019.243543. View

15.

Zhang X, Jing S, Lin H, Sun W, Jiang W, Yu C . Anti-fatigue effect of anwulignan via the NRF2 and PGC-1α signaling pathway in mice. Food Funct. 2019; 10(12):7755-7766. DOI: 10.1039/c9fo01182j. View

16.

Kaushik D, Shah P, Mukherjee N, Ji N, Dursun F, Kumar A . Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer Prostatic Dis. 2021; 25(3):531-538. PMC: 9124736. DOI: 10.1038/s41391-021-00470-w. View

17.

Song Y, Zhuang G, Li J, Zhang M . BAIAP2L2 facilitates the malignancy of prostate cancer (PCa) via VEGF and apoptosis signaling pathways. Genes Genomics. 2021; 43(4):421-432. DOI: 10.1007/s13258-021-01061-8. View

18.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

19.

Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T . Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021; 39(11):1464-1478.e8. PMC: 8578470. DOI: 10.1016/j.ccell.2021.09.005. View

20.

Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S . Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Mol Cancer. 2022; 21(1):132. PMC: 9206324. DOI: 10.1186/s12943-022-01597-7. View